MIF and Alzheimer disease: A significant increase in cerebrospinal fluid (CSF) MIF levels in AD plus a modulation in Aβ pathology in a murine transgenic model treated with a MIF inhibitor suggested that MIF may not only be a biomarker for AD but also a therapeutic target [46].